{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T12:21:55Z","timestamp":1761394915192},"reference-count":26,"publisher":"Oxford University Press (OUP)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Antimicrob. Chemother."],"DOI":"10.1093\/jac\/dkw512","type":"journal-article","created":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T12:07:31Z","timestamp":1478261251000},"page":"dkw512","source":"Crossref","is-referenced-by-count":3,"title":["Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir\/emtricitabine\/rilpivirine single-tablet regimen"],"prefix":"10.1093","author":[{"given":"D.","family":"Armenia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Di Carlo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Calcagno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Vendemiati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Forbici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bertoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Berno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Carta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Continenza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Fedele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Bellagamba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Cicalini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ammassari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Libertone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Zaccarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Ghisetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Andreoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Ceccherini-Silberstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Bonora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Di Perri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Antinori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. F.","family":"Perno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. M.","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,12,20]]},"reference":[{"key":"2016122017351459000_dkw512v1.1","unstructured":"WHO. Guidelines 2016. http:\/\/apps.who.int\/iris\/bitstream\/10665\/246200\/1\/9789241511124-eng.pdf?ua=12."},{"key":"2016122017351459000_dkw512v1.2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-013-0132-4"},{"key":"2016122017351459000_dkw512v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2009.09.008"},{"key":"2016122017351459000_dkw512v1.4","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.844685"},{"key":"2016122017351459000_dkw512v1.5","doi-asserted-by":"publisher","DOI":"10.1310\/hct1403-81"},{"key":"2016122017351459000_dkw512v1.6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/15284336.2015.1115585","article-title":"Clinical outcomes of virologically-suppressed patients with pre-existing HIV-1 drug resistance mutations switching to rilpivirine\/emtricitabine\/tenofovir disoproxil fumarate in the SPIRIT study","volume":"17","author":"Porter","year":"2016","journal-title":"HIV Clin Trials"},{"key":"2016122017351459000_dkw512v1.7","doi-asserted-by":"publisher","DOI":"10.1179\/1528433614Z.0000000009"},{"key":"2016122017351459000_dkw512v1.8","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Service (DHHS). https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf."},{"key":"2016122017351459000_dkw512v1.9","unstructured":"EACS. EACS Guidelines Version 8.0. http:\/\/www.eacsociety.org\/files\/guidelines_8.0-english-revised_20160610.pdf."},{"key":"2016122017351459000_dkw512v1.10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.8722"},{"key":"2016122017351459000_dkw512v1.11","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/hiv.12183","article-title":"Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort study","volume":"16","author":"Gantner","year":"2015","journal-title":"HIV Med"},{"key":"2016122017351459000_dkw512v1.12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3851\/IMP3010","article-title":"Efficacy and safety of a switch to rilpivirine-based regimens in treatment-experienced HIV-1-infected patients: a cohort study","volume":"21","author":"Gazaignes","year":"2015","journal-title":"Antivir Ther (Lond)"},{"key":"2016122017351459000_dkw512v1.13","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3851\/IMP2531","article-title":"Impact of pre-therapy viral load on virological response to modern first-line HAART","volume":"18","author":"Santoro","year":"2013","journal-title":"Antivir Ther (Lond)"},{"key":"2016122017351459000_dkw512v1.14","unstructured":"Khatchatourian M Hanf T Jovelin . Impact of baseline viral load, time to viral suppression, and drug class on virologic rebound. In: Abstracts of the Fifteenth European AIDS Conference, Barcelona, Spain, 2015. Abstract PS10\/1. European AIDS Clinical Society, Brussels, Belgium."},{"key":"2016122017351459000_dkw512v1.15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12981-016-0100-4","article-title":"Factors associated with HIV viral load \u2018blips\u2019 and the relationship between self-reported adherence and efavirenz blood levels on blip occurrence: a case\u2013control study","volume":"13","author":"Farmer","year":"2016","journal-title":"AIDS Res Ther"},{"key":"2016122017351459000_dkw512v1.16","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu020"},{"key":"2016122017351459000_dkw512v1.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2009.10.012"},{"key":"2016122017351459000_dkw512v1.18","first-page":"132","article-title":"2015 update of the drug resistance mutations in HIV-1","volume":"23","author":"Wensing","year":"2015","journal-title":"Top Antivir Med"},{"key":"2016122017351459000_dkw512v1.19","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis104"},{"key":"2016122017351459000_dkw512v1.20","first-page":"39","article-title":"On the comparison of two survival functions","volume":"3","author":"McCracken","year":"2010","journal-title":"USC Upstate Stud Res J"},{"key":"2016122017351459000_dkw512v1.21","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000087"},{"key":"2016122017351459000_dkw512v1.22","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv018"},{"key":"2016122017351459000_dkw512v1.23","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku187"},{"key":"2016122017351459000_dkw512v1.24","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq140"},{"key":"2016122017351459000_dkw512v1.25","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/hiv.12157","article-title":"Successful switch to rilpivirine\/tenofovir\/emtricitabine in HIV-1-infected patients with an isolated K103N mutation acquired during prior nonnucleoside reverse transcriptase inhibitor therapy","volume":"15","author":"Rokx","year":"2014","journal-title":"HIV Med"},{"key":"2016122017351459000_dkw512v1.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2015.11.009"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/72\/3\/855\/13761270\/dkw512.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T10:34:48Z","timestamp":1718879688000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/dkw512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,20]]},"references-count":26,"alternative-id":["10.1093\/jac\/dkw512"],"URL":"https:\/\/doi.org\/10.1093\/jac\/dkw512","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,20]]}}}